JP7352294B2 - ムスカリン性アセチルコリン受容体m4のアンタゴニスト - Google Patents

ムスカリン性アセチルコリン受容体m4のアンタゴニスト Download PDF

Info

Publication number
JP7352294B2
JP7352294B2 JP2020541908A JP2020541908A JP7352294B2 JP 7352294 B2 JP7352294 B2 JP 7352294B2 JP 2020541908 A JP2020541908 A JP 2020541908A JP 2020541908 A JP2020541908 A JP 2020541908A JP 7352294 B2 JP7352294 B2 JP 7352294B2
Authority
JP
Japan
Prior art keywords
azabicyclo
pyridazin
amine
hexane
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020541908A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513519A (ja
JP2021513519A5 (cg-RX-API-DMAC7.html
Inventor
クレイグ ダブリュー リンズレイ
ピー ジェフリー コーン
ダレン ダブリュー エンガース
ジュリー エル エンガース
アーロン エム ベンダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of JP2021513519A publication Critical patent/JP2021513519A/ja
Publication of JP2021513519A5 publication Critical patent/JP2021513519A5/ja
Application granted granted Critical
Publication of JP7352294B2 publication Critical patent/JP7352294B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020541908A 2018-02-02 2019-02-01 ムスカリン性アセチルコリン受容体m4のアンタゴニスト Active JP7352294B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862625656P 2018-02-02 2018-02-02
US62/625,656 2018-02-02
PCT/US2019/016300 WO2019152809A1 (en) 2018-02-02 2019-02-01 Antagonists of the muscarinic acetylcholine receptor m4

Publications (3)

Publication Number Publication Date
JP2021513519A JP2021513519A (ja) 2021-05-27
JP2021513519A5 JP2021513519A5 (cg-RX-API-DMAC7.html) 2022-02-16
JP7352294B2 true JP7352294B2 (ja) 2023-09-28

Family

ID=67480022

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020541908A Active JP7352294B2 (ja) 2018-02-02 2019-02-01 ムスカリン性アセチルコリン受容体m4のアンタゴニスト

Country Status (10)

Country Link
US (1) US11414406B2 (cg-RX-API-DMAC7.html)
EP (1) EP3746421B1 (cg-RX-API-DMAC7.html)
JP (1) JP7352294B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200116945A (cg-RX-API-DMAC7.html)
CN (1) CN111788182B (cg-RX-API-DMAC7.html)
AU (1) AU2019216492A1 (cg-RX-API-DMAC7.html)
CA (1) CA3090130A1 (cg-RX-API-DMAC7.html)
IL (1) IL276411B2 (cg-RX-API-DMAC7.html)
WO (1) WO2019152809A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202004638B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3651762B1 (en) 2017-07-12 2024-07-03 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
JP7270989B2 (ja) 2017-10-20 2023-05-11 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体m4のアンタゴニスト
WO2019126731A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
US11458149B1 (en) 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
BR112021024108A2 (pt) 2019-05-31 2022-03-22 Ikena Oncology Inc Inibidores de tead e usos dos mesmos
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
US12319701B2 (en) 2019-10-04 2025-06-03 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
CA3169667A1 (en) * 2020-02-28 2021-09-02 Dominic Reynolds Pyridazine derivatives for modulating nucleic acid splicing
CA3199724A1 (en) 2020-11-26 2022-06-02 Yusheng Xiong Anticholinergic agents

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056811A1 (en) 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2006035280A1 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases
WO2006035282A2 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2007007281A2 (en) 2005-07-11 2007-01-18 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
JP2009515820A (ja) 2005-10-21 2009-04-16 ノバルティス アクチエンゲゼルシャフト 新規1−アザ−ビシクロアルキル誘導体
JP2016510044A (ja) 2013-03-05 2016-04-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 癌などの疾患の処置のためのトリアゾロ[4,5−d]ピリミジン誘導体
WO2017079641A1 (en) 2015-11-06 2017-05-11 Neurocrine Biosciences, Inc. N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
WO2017100726A1 (en) 2015-12-10 2017-06-15 Ptc Therapeutics, Inc. Methods for treatng huntington's disease
US20170355708A1 (en) 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676444B1 (fr) * 1991-05-16 1995-03-10 Sanofi Elf Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
US20040044029A1 (en) 2002-08-14 2004-03-04 Dart Michael J. Azabicyclic compounds are central nervous system active agents
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
WO2008065500A2 (en) 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
JP2010513458A (ja) * 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク H−pgdsの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンd2の仲介による疾患を治療するためのその使用
CN101230058A (zh) 2007-01-23 2008-07-30 上海恒瑞医药有限公司 双环氮杂烷类衍生物、其制备方法及其在医药上的用途
CN103102352B (zh) 2011-11-15 2015-08-12 山东亨利医药科技有限责任公司 酪氨酸激酶抑制剂吲哚满酮衍生物
TW201444820A (zh) 2013-03-13 2014-12-01 Abbvie Inc 吡啶cdk9激酶抑制劑
PL3536685T3 (pl) 2014-04-04 2022-05-16 Pfizer Inc. Bicykliczne skondensowane związki heteroarylowe lub arylowe i ich zastosowanie jako inhibitory IRAK4
HRP20210935T1 (hr) * 2014-05-23 2021-08-06 F. Hoffmann - La Roche Ag Spojevi 5-kloro-2-difluorometoksifenil pirazolopirimidina koji predstavljaju inhibitore jak
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
BR112018016689A2 (pt) 2016-02-16 2019-02-12 Univ Vanderbilt moduladores alostéricos positivos do receptor muscarínico de acetilcolina m1
AU2018313802A1 (en) * 2017-08-08 2020-02-20 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
WO2019079410A1 (en) * 2017-10-17 2019-04-25 Vanderbilt University ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4
JP7270989B2 (ja) * 2017-10-20 2023-05-11 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体m4のアンタゴニスト
ES2982890T3 (es) * 2017-10-31 2024-10-18 Univ Vanderbilt Antagonistas del receptor muscarínico de acetilcolina M4
EP3732163A4 (en) * 2017-12-20 2021-07-14 Vanderbilt University MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056811A1 (en) 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2006035280A1 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases
WO2006035282A2 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2007007281A2 (en) 2005-07-11 2007-01-18 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
JP2009515820A (ja) 2005-10-21 2009-04-16 ノバルティス アクチエンゲゼルシャフト 新規1−アザ−ビシクロアルキル誘導体
JP2016510044A (ja) 2013-03-05 2016-04-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 癌などの疾患の処置のためのトリアゾロ[4,5−d]ピリミジン誘導体
WO2017079641A1 (en) 2015-11-06 2017-05-11 Neurocrine Biosciences, Inc. N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
WO2017100726A1 (en) 2015-12-10 2017-06-15 Ptc Therapeutics, Inc. Methods for treatng huntington's disease
US20170355708A1 (en) 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REGISTRY(STN)[online],Entered STN: 25 Dec 2017以前,[検索日:2022年12月27日],CAS登録番号 2164592-45-2, 2152087-70-0, 2148484-96-0,2029853-92-5, 2028000-90-8, 2025026-23-5, 2024724-04-5, 2001685-84-1,1995218-19-3

Also Published As

Publication number Publication date
US20200369650A1 (en) 2020-11-26
KR20200116945A (ko) 2020-10-13
IL276411A (en) 2020-09-30
EP3746421A1 (en) 2020-12-09
CN111788182A (zh) 2020-10-16
US11414406B2 (en) 2022-08-16
JP2021513519A (ja) 2021-05-27
CN111788182B (zh) 2023-09-26
CA3090130A1 (en) 2019-08-08
AU2019216492A1 (en) 2020-08-20
EP3746421B1 (en) 2023-11-29
WO2019152809A1 (en) 2019-08-08
IL276411B1 (en) 2023-12-01
IL276411B2 (en) 2024-04-01
EP3746421A4 (en) 2021-10-27
ZA202004638B (en) 2023-02-22

Similar Documents

Publication Publication Date Title
EP3746421B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
ES2986581T3 (es) Antagonistas del receptor muscarínico de acetilcolina M4
US11325896B2 (en) Antagonists of the muscarinic acetylcholine receptor M4
US11352344B2 (en) Antagonists of the muscarinic acetylcholine receptor M4
US11225484B2 (en) Substituted octahydropyrrolo[3,4-b]pyrroles as antagonists of the muscarinic acetylcholine receptor M4
EP3697781B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
EP4037677B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
JP2023549534A (ja) ムスカリン性アセチルコリン受容体m4のアンタゴニスト
EP4441046A1 (en) Antagonists of the muscarinic acetylcholine receptor m4

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220201

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230508

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230809

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230908

R150 Certificate of patent or registration of utility model

Ref document number: 7352294

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150